BioNTech US Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Phase 1

Active, not recruiting

Conditions: Unresectable Melanoma
Metastatic Melanoma

Interventions: Biological: NEO-PTC-01
Drug: IL-2
Drug: PD-1 Inhibitors

First Posted Date: 2020-11-12

Last Posted Date: 2024-12-19

Lead Sponsor: BioNTech US Inc.

Target Recruit Count: 22

Registration Number: NCT04625205

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Phase 1

Terminated

Conditions: Metastatic Melanoma

Interventions: Biological: NEO-PV-01
Biological: Nivolumab
Other: Adjuvant
Biological: ipilimumab
Biological: APX005M

First Posted Date: 2018-07-24

Last Posted Date: 2020-09-03

Lead Sponsor: BioNTech US Inc.

Target Recruit Count: 22

Registration Number: NCT03597282

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 5 locations

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Cancer
Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions: Biological: NEO-PV-01
Biological: Pembrolizumab
Other: Adjuvant
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2017-12-21

Last Posted Date: 2021-02-26

Lead Sponsor: BioNTech US Inc.

Target Recruit Count: 38

Registration Number: NCT03380871

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 2 locations

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Phase 1

Completed

Conditions: Urinary Bladder Cancer
Bladder Tumors
Melanoma
Transitional Cell Carcinoma of the Bladder
Malignant Melanoma
Carcinoma, Non-Small-Cell Lung
Skin Cancer
Lung Cancer

Interventions: Biological: NEO-PV-01
Biological: Nivolumab
Other: Adjuvant

First Posted Date: 2016-09-13

Last Posted Date: 2021-02-25

Lead Sponsor: BioNTech US Inc.

Target Recruit Count: 34

Registration Number: NCT02897765

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 6 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy